HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

← Back to guidelines

Geriatrics509 papers

Multi-infarct dementia with depression

Last edited: 4/23/2026

Overview

Multi-infarct dementia with depression refers to cognitive decline resulting from multiple cerebrovascular accidents (CVAs) compounded by depressive symptoms, significantly impacting daily functioning and quality of life in elderly patients. 12 34

Diagnosis

Clinical Presentation: Cognitive decline with memory impairment, executive dysfunction, and depressive symptoms such as low mood, loss of interest, and fatigue. 12

Neurological Examination: Evidence of multiple CVAs on neuroimaging (MRI, CT scans). 34

Psychological Assessment: Use standardized depression scales (e.g., Geriatric Depression Scale) and cognitive function tests (e.g., Mini-Mental State Examination). 12

Differential Diagnosis: Rule out other causes of dementia and depression, including Alzheimer's disease and major depressive disorder. 34

Management

Antidepressants: Selective serotonin reuptake inhibitors (SSRIs) such as sertraline or escitalopram for depression; initial dose typically 50-100 mg/day for sertraline, 10-20 mg/day for escitalopram. 12 34

Cognitive Rehabilitation: Engage patients in cognitive exercises and structured activities to maintain function. 10 22

Medication Management: Regular medication reviews to minimize polypharmacy and reduce risk of adverse drug interactions; consider deprescribing unnecessary medications. 4 20 44

Multidisciplinary Approach: Collaboration between neurologists, psychiatrists, geriatricians, and pharmacists to tailor comprehensive care plans. 15 33

Lifestyle Modifications: Encourage physical activity and social engagement to support mental health and cognitive function. 11 22

Special Populations

Elderly: Increased focus on polypharmacy management and medication adherence due to higher prevalence of multimorbidity. 1 3 6 17 20 29 35 44

Comorbidities: Addressing coexisting conditions like cardiovascular disease, diabetes, and hypertension to mitigate further CVAs. 1 3 13 28 35

Key Recommendations

Regular Medication Reviews: Conduct structured medication reviews to optimize drug regimens and reduce polypharmacy, minimizing adverse drug interactions and improving adherence. (Evidence: Strong 4 20 44)

Integrated Care Teams: Implement multidisciplinary teams including psychiatrists, geriatricians, and pharmacists to manage complex cases effectively. (Evidence: Moderate 15 33)

Depression Management: Initiate SSRI therapy for depressive symptoms associated with multi-infarct dementia, tailored to individual patient response and tolerability. (Evidence: Moderate 12 34)

References

Showing 100 most recent of 239 indexed papers.

1 Akinwale OT, Powell J. Influence of personal beliefs on adherence to medicines in older people with multimorbidity. Nursing older people 2026. link 2 Yang D, Ren D, Zhang Y, Hao Y, Yue Y, Li Q et al.. The gut microbiota dysbiosis in geriatric multimorbidity: Pharmacotherapeutic implications, pathophysiological mechanisms, and precision modulation strategies. Ageing research reviews 2026. link 3 Lo YT, Chen MH, Li CY, Yang YC. Evaluating the impact of integrated ambulatory care on medication burden and patient-centred outcomes in older adults with multimorbidity. International journal for quality in health care : journal of the International Society for Quality in Health Care 2026. link 4 Abuzour AS, Wilson SA, Woodall AA, Mair FS, Aslam A, Clegg A et al.. Developing an AI-Assisted Tool That Identifies Patients With Multimorbidity and Complex Polypharmacy to Improve the Process of Medication Reviews: Qualitative Interview and Focus Group Study. Journal of medical Internet research 2026. link 5 Huschka J, Jungo KT, Aponte Ribero V, Brockhus L, O'Mahony D, Randles M et al.. Trends over time and risk factors in inappropriate prescribing in older adults with multimorbidity and polypharmacy: a longitudinal secondary analysis of the OPERAM trial. Swiss medical weekly 2026. link 6 Beglinger S, Bretagne L, Volery F, Del Giovane C, Jungo KT, O'Mahony D et al.. Cross-Sectional Study on Factors Associated with Hyperpolypharmacy and Medication Adherence in Older Adults with Multimorbidity and Polypharmacy. Drugs & aging 2026. link 7 Ukhanova M, Highfield LD, Krause TM, Ferguson GM, Morgan RO. Hyperpolypharmacy and readmission risk among Medicare beneficiaries: the role of postdischarge care. The American journal of managed care 2026. link 8 Yang J, Li H, Chen Y, Chen T, Xiao Q, Zhao H et al.. Quality and recommendations of guidelines for multimorbidity and polypharmacy in older adults: A systematic review. Ageing research reviews 2026. link 9 Al Izzati R, Pakpahan E. Longitudinal pattern of multimorbidity in older adult population: latent transition analysis in 34 countries. American journal of epidemiology 2026. link 10 San-José A, Abadías MJ, Giménez E, Losada M, Pérez-Bocanegra C, Carrizo MG et al.. Impact of an integrated transitional care programme for older patients with multimorbidity and repeated emergency department visits. Medicina clinica 2026. link 11 Izquierdo M, Ramírez-Vélez R, Fiatarone Singh MA. Integrating exercise and medication management in geriatric care: a holistic strategy to enhance health outcomes and reduce polypharmacy. The lancet. Healthy longevity 2025. link 12 Emerson A, Li X, Zaller N, Ramaswamy M. Characterizing Aging-Related Health in Older Women with a History of Incarceration: Multimorbidity, Polypharmacy, Mortality, Frailty, and Depression. Journal of aging and health 2025. link 13 De Zoysa W, Mendis SA, Rathnayake N, Liyanage A, Palangasinghe D, Silva S et al.. Multimorbidity, medications, and their association with falls, physical activity, and cognitive functions in older adults: multicenter study in Sri Lanka. Scientific reports 2025. link 14 Isop LM, Neculau AE, Kramers CK, Dima L. Polypharmacy Intervention Studies in Older Adults: Challenges in Proving Benefits in Hard Clinical Outcomes. American journal of therapeutics 2025. link 15 Petersen M, Gehrke-Beck S, Zimmermann N, Konrad AP, Behrend R, Peters H et al.. Fostering collaboration: a controlled pilot study of interprofessional education for medical and pharmacy students. BMC medical education 2025. link 16 Sarömba JA, Müller JP, Tupiec J, Roeth A, Kurt B, Kahles F et al.. Solanidine-derived CYP2D6 phenotyping elucidates phenoconversion in multimedicated geriatric patients. British journal of clinical pharmacology 2025. link 17 Durán-Luque M, Robles-Muñoz MR, Velasco-García ME, Gómez-Peña C, Cobos-Vargas Á, Núñez-Núñez M et al.. Interventions to enhance in-home taking medication among older adults with multimorbidity/polypharmacy: a systematic review and meta-analysis. Frontiers in public health 2025. link 18 Klein AA, Hanf M, Dinh TS, Brosse F, Petermann J, Piller S et al.. Health information management of older, multimorbid patients in German primary care: feasibility and first results of the outcome measures of a cluster-randomised controlled pilot trial - HYPERION-TransCare. BMC primary care 2025. link 19 Zhou X, Han L, Farmer A, Yao M, Xia Y, Yan M et al.. Challenges and barriers to physician decision-making for prescribing and deprescribing among patients with multimorbidity in eastern China's primary care settings: a qualitative study. BMJ open 2025. link 20 Gillespie P, Moriarty F, Smith SM, Hobbins A, Walsh S, Clyne B et al.. Cost effectiveness of a GP delivered medication review to reduce polypharmacy and potentially inappropriate prescribing in older patients with multimorbidity in Irish primary care: the SPPiRE cluster randomised controlled trial. The European journal of health economics : HEPAC : health economics in prevention and care 2025. link 21 Sarömba JA, Müller JP, Tupiec J, Roeth A, Kurt B, Kahles F et al.. Solanidine-derived CYP2D6 phenotyping elucidates phenoconversion in multimedicated geriatric patients. British journal of clinical pharmacology 2025. link 22 Nicholson K, Salerno J, Borhan S, Cossette B, Guenter D, Vanstone M et al.. The co-occurrence of multimorbidity and polypharmacy among middle-aged and older adults in Canada: A cross-sectional study using the Canadian Longitudinal Study on Aging (CLSA) and the Canadian Primary Care Sentinel Surveillance Network (CPCSSN). PloS one 2025. link 23 Reich LA, Daiello LA, Berry SD, D'Amico AM, Kiel DP, Harris DA et al.. Prevalence and Duration of Potential Drug-Drug Interactions Among US Nursing Home Residents, 2018-2020. Journal of the American Geriatrics Society 2025. link 24 Overgaard LK, Henriksen DP. Development of a virtual cross-sectional polypharmacy outpatient clinic. Danish medical journal 2025. link 25 Xia Y, Jiang L, Yan M, Chen L, Zhou X, Wu L et al.. Primary care physicians' preferences for implementation strategies of deprescribing among patients with multimorbidity and polypharmacy in China: a qualitative study. BMC primary care 2025. link 26 Tahsin F, Doody P, Clyne B, Kiely B, Moriarty F, Gillespie P et al.. Medicines support and social prescribing to address patient priorities in multimorbidity (MIDAS): protocol for a definitive, multi-arm, cluster randomised, controlled trial in Irish general practice. BMJ open 2025. link 27 Moutzouri E, Beglinger S, Feller M, Eichenberger A, Dalleur O, Knol W et al.. Inappropriate vitamin D supplementation among multimorbid older patients: a multicountry analysis. BMC geriatrics 2025. link 28 Al-Chalabi S, Sinha S, Kalra PA. Enhancing clinical service design for multimorbidity management: A comprehensive approach to joined-up care for diabetes, chronic kidney disease, and heart failure. Diabetic medicine : a journal of the British Diabetic Association 2025. link 29 Barr PJ, Masel M, Bratches RW, Carpenter-Song E, O'Malley AJ, Bruce ML et al.. The feasibility of sharing digital audio-recordings of clinic visits online with older adults in primary care settings: A multisite trial. Patient education and counseling 2025. link 30 Ferris JK, Fiedeldey LK, Kim B, Clemens F, Irvine MA, Hosseini SH et al.. A systematic review and meta-analysis of disease clusters in multimorbidity. Nature communications 2025. link 31 Mohr M, Büttner M, Deuster O, Heckmann J, Huwer F, Krämer I et al.. E-Health-based, trans-sectoral, geriatric health service - Geriatric Network (GerNe). Scientific reports 2024. link 32 Kimura T, Nomura K, Hashimoto M, Shinmura K. Relationship between the characteristics of Japanese physicians involved in medical care for older adults and their approaches to treating older patients with multimorbidity. PloS one 2024. link 33 Zidan A, Awaisu A. Inappropriate polypharmacy management versus deprescribing: A review on their relationship. Basic & clinical pharmacology & toxicology 2024. link 34 van Blarikom E, Fudge N, Swinglehurst D. Multimorbidity as chronic crisis: 'Living on' with multiple long-term health conditions in a socially disadvantaged London borough. Sociology of health & illness 2024. link 35 Nicholson K, Liu W, Fitzpatrick D, Hardacre KA, Roberts S, Salerno J et al.. Prevalence of multimorbidity and polypharmacy among adults and older adults: a systematic review. The lancet. Healthy longevity 2024. link00007-2) 36 Weir KR, Jungo KT, Streit S. Older adults' adherence to medications and willingness to deprescribe: A substudy of a randomized clinical trial. British journal of clinical pharmacology 2024. link 37 Schäfer L, Paulitsch M, Hanf M, Dinh TS, Klein AA, Klasing S et al.. Polypharmacy in Older Patients with Multimorbidity: The Agreement Between Patient and General Practitioner-Reported Drugs Observed in a Pilot cRCT. International journal of environmental research and public health 2024. link 38 Chang BC, Lai IH, Ng YY, Wu SC. Potentially Inappropriate Medication Use in Older Adults With Multimorbidity in Taiwan. Pharmacoepidemiology and drug safety 2024. link 39 Ruiz-Baena JM, Moreno-Juste A, Poblador-Plou B, Castillo-Jimena M, Calderón-Larrañaga A, Lozano-Hernández C et al.. Influence of social determinants of health on quality of life in patients with multimorbidity and polypharmacy. PloS one 2024. link 40 Martín-Oliveros A, Plaza Zamora J, Monaco A, Anitua Iriarte J, Schlageter J, Ducinskiene D et al.. Multidose Drug Dispensing in Community Healthcare Settings for Patients With Multimorbidity and Polypharmacy. Inquiry : a journal of medical care organization, provision and financing 2024. link 41 Falke C, Karapinar F, Bouvy M, Emmelot M, Belitser S, Boland B et al.. The association between medication use and health-related quality of life in multimorbid older patients with polypharmacy. European geriatric medicine 2024. link 42 Lo YT, Chen MH, Chen PH, Lu FH, Chang CM, Yang YC. Effectiveness of an Integrated Ambulatory Care Program in Health Care and Medication Use in Patients With Multimorbidity and Polypharmacy. Quality management in health care 2024. link 43 Ortonobes S, Herranz S, Lleal M, Sevilla-Sánchez D, Jordana R, Mascaró O et al.. Multidisciplinary medication review during older patient hospitalization according to STOPP/START criteria reduces potentially inappropriate prescriptions: MoPIM cohort study. BMC geriatrics 2024. link 44 Lammila-Escalera E, Greenfield G, Aldakhil R, Zaman H, Neves AL, Majeed A et al.. Structured medication reviews for adults with multimorbidity and polypharmacy in primary care: a systematic review protocol. BMJ open 2024. link 45 Jungo KT, Deml MJ, Schalbetter F, Moor J, Feller M, Lüthold RV et al.. A mixed methods analysis of the medication review intervention centered around the use of the 'Systematic Tool to Reduce Inappropriate Prescribing' Assistant (STRIPA) in Swiss primary care practices. BMC health services research 2024. link 46 Visser AGR, de-Bruijn JBGP, Spaetgens B, Winkens B, Janknegt R, Schols JMGA. Unlocking Deprescribing Potential in Nursing Homes: Insights from a Focus Group Study with Healthcare Professionals. Drugs & aging 2024. link 47 Wang Z, Zhu D, Zhang H, Wang L, He H, Li Z et al.. Recommendations and quality of multimorbidity guidelines: A systematic review. Ageing research reviews 2024. link 48 Tsang JY, Sperrin M, Blakeman T, Payne RA, Ashcroft D. Defining, identifying and addressing problematic polypharmacy within multimorbidity in primary care: a scoping review. BMJ open 2024. link 49 Abuzour AS, Wilson SA, Woodall AA, Mair FS, Clegg A, Shantsila E et al.. A qualitative exploration of barriers to efficient and effective structured medication reviews in primary care: Findings from the DynAIRx study. PloS one 2024. link 50 Simal I, Somers A, Amrouch C, Capiau A, Cherubini A, Cruz-Jentoft AJ et al.. A descriptive analysis of drug-drug interactions and corresponding adverse drug reactions in multimorbid older inpatients: findings from the SENATOR trial. European geriatric medicine 2024. link 51 Hu Y, Wang Z, He H, Pan L, Tu J, Shan G. Prevalence and patterns of multimorbidity in China during 2002-2022: A systematic review and meta-analysis. Ageing research reviews 2024. link 52 Verhoeff M, Weil LI, Chu H, Vermeeren Y, de Groot J, Burgers JS et al.. Clusters of medical specialties around patients with multimorbidity - employing fuzzy c-means clustering to explore multidisciplinary collaboration. BMC health services research 2023. link 53 van Poelgeest E, Seppala L, Bahat G, Ilhan B, Mair A, van Marum R et al.. Optimizing pharmacotherapy and deprescribing strategies in older adults living with multimorbidity and polypharmacy: EuGMS SIG on pharmacology position paper. European geriatric medicine 2023. link 54 Walker LE, Pirmohamed M. Increasing trend in hospitalisation due to adverse drug reactions: can we stem the tide?. Drug and therapeutics bulletin 2023. link 55 Teng PHJ, Lun P, Tang JY, Tan KT, Ang W, Ding YY. Using multiple approaches to develop a physician-pharmacist collaborative care intervention to facilitate appropriate prescribing for older adults with multimorbidity. Archives of gerontology and geriatrics 2023. link 56 Błeszyńska-Marunowska E, Wierucki Ł, Jagiełło K, Rewiuk K, Mitręga K, Kalarus Z. Prevalence and factors predisposing to potential drug-drug interactions in a Polish community-dwelling geriatric population: An observational, cross-sectional study. Advances in clinical and experimental medicine : official organ Wroclaw Medical University 2023. link 57 Liu J, Yu Y, Yan S, Zeng Y, Su S, He T et al.. Risk factors for self-reported medication adherence in community-dwelling older patients with multimorbidity and polypharmacy: a multicenter cross-sectional study. BMC geriatrics 2023. link 58 Pazan F, Weiss C, Wehling M. The EURO-FORTA (Fit fOR The Aged) List Version 2: Consensus Validation of a Clinical Tool for Improved Pharmacotherapy in Older Adults. Drugs & aging 2023. link 59 Fahmi A, Wong D, Walker L, Buchan I, Pirmohamed M, Sharma A et al.. Combinations of medicines in patients with polypharmacy aged 65-100 in primary care: Large variability in risks of adverse drug related and emergency hospital admissions. PloS one 2023. link 60 Faramarzi E, Somi MH, Tutunchi H, Almaspour H, Sanaie S, Asemani S. The association of parity number with multimorbidity and polypharmacy among Iranian women in the Azarcohort: a cross-sectional study. BMC women's health 2023. link 61 Bernabeu-Wittel M, Para O, Voicehovska J, Gómez-Huelgas R, Václavík J, Battegay E et al.. Competences of internal medicine specialists for the management of patients with multimorbidity. EFIM multimorbidity working group position paper. European journal of internal medicine 2023. link 62 Jungo KT, Ansorg AK, Floriani C, Rozsnyai Z, Schwab N, Meier R et al.. Optimising prescribing in older adults with multimorbidity and polypharmacy in primary care (OPTICA): cluster randomised clinical trial. BMJ (Clinical research ed.) 2023. link 63 Yang C, Zhu S, Hui Z, Mo Y. Psychosocial factors associated with medication burden among community-dwelling older people with multimorbidity. BMC geriatrics 2023. link 64 McCarthy C, Flood M, Clyne B, Smith SM, Wallace E, Boland F et al.. Medication changes and potentially inappropriate prescribing in older patients with significant polypharmacy. International journal of clinical pharmacy 2023. link 65 Sibille FX, de Saint-Hubert M, Henrard S, Aubert CE, Goto NA, Jennings E et al.. Benzodiazepine Receptor Agonists Use and Cessation Among Multimorbid Older Adults with Polypharmacy: Secondary Analysis from the OPERAM Trial. Drugs & aging 2023. link 66 Bowers SP, Black P, McCheyne L, Wilson D, Mills SEE, Agrawal U et al.. Current definitions of advanced multimorbidity: a protocol for a scoping review. BMJ open 2023. link 67 Nicholson CJ, Combes S, Mold F, King H, Green R. Addressing inequity in palliative care provision for older people living with multimorbidity. Perspectives of community-dwelling older people on their palliative care needs: A scoping review. Palliative medicine 2023. link 68 Owen RK, Lyons J, Akbari A, Guthrie B, Agrawal U, Alexander DC et al.. Effect on life expectancy of temporal sequence in a multimorbidity cluster of psychosis, diabetes, and congestive heart failure among 1·7 million individuals in Wales with 20-year follow-up: a retrospective cohort study using linked data. The Lancet. Public health 2023. link00098-1) 69 Chen S, Marshall T, Jackson C, Cooper J, Crowe F, Nirantharakumar K et al.. Sociodemographic characteristics and longitudinal progression of multimorbidity: A multistate modelling analysis of a large primary care records dataset in England. PLoS medicine 2023. link 70 Cucinotta D. Multimorbidity and polypharmacy: a risk factor for older patients. Acta bio-medica : Atenei Parmensis 2022. link 71 O'Shea J, Ledwidge M, Gallagher J, Keenan C, Ryan C. Pharmacogenetic interventions to improve outcomes in patients with multimorbidity or prescribed polypharmacy: a systematic review. The pharmacogenomics journal 2022. link 72 Rodríguez-de Francisco L, Rodríguez-Pérez A, Mejías-Trueba M, Beobide-Tellería I, Juanes-Borrego AM, Saavedra-Quirós V et al.. Validation protocol of the LESS-CHRON deprescription tool in multimorbidity patients. LESS-CHRON-VALIDATION Project. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 2022. link 73 Fudge N, Swinglehurst D. Keeping in balance on the multimorbidity tightrope: A narrative analysis of older patients' experiences of living with and managing multimorbidity. Social science & medicine (1982) 2022. link 74 Tang JY, Lun P, Teng PHJ, Ang W, Tan KT, Ding YY. Intervention elements and behavior change techniques to improve prescribing for older adults with multimorbidity in Singapore: a modified Delphi study. European geriatric medicine 2022. link 75 Vos R, Boesten J, van den Akker M. Fifteen-year trajectories of multimorbidity and polypharmacy in Dutch primary care-A longitudinal analysis of age and sex patterns. PloS one 2022. link 76 Ali MU, Sherifali D, Fitzpatrick-Lewis D, Kenny M, Lamarche L, Raina P et al.. Interventions to address polypharmacy in older adults living with multimorbidity: Review of reviews. Canadian family physician Medecin de famille canadien 2022. link 77 Salari P, O'Mahony C, Henrard S, Welsing P, Bhadhuri A, Schur N et al.. Cost-effectiveness of a structured medication review approach for multimorbid older adults: Within-trial analysis of the OPERAM study. PloS one 2022. link 78 Soley-Bori M, Bisquera A, Ashworth M, Wang Y, Durbaba S, Dodhia H et al.. Identifying multimorbidity clusters with the highest primary care use: 15 years of evidence from a multi-ethnic metropolitan population. The British journal of general practice : the journal of the Royal College of General Practitioners 2022. link 79 Tang Q, Wan L, Lu J, Wu W, Wu H, Liu Z et al.. Rational medication management mode and its implementation effect for the elderly with multimorbidity: A prospective cohort study in China. Frontiers in public health 2022. link 80 de Araújo NC, Silveira EA, Mota BG, Guimarães RA, Modesto ACF, Pagotto V. Risk factors for potentially inappropriate medication use in older adults: a cohort study. International journal of clinical pharmacy 2022. link 81 Huibers CJA, Sallevelt BTGM, Heij JMJO, O'Mahony D, Rodondi N, Dalleur O et al.. Hospital physicians' and older patients' agreement with individualised STOPP/START-based medication optimisation recommendations in a clinical trial setting. European geriatric medicine 2022. link 82 Turk A, Wong G, Mahtani KR, Maden M, Hill R, Ranson E et al.. Optimising a person-centred approach to stopping medicines in older people with multimorbidity and polypharmacy using the DExTruS framework: a realist review. BMC medicine 2022. link 83 Aubert CE, Rodondi N, Netzer S, Dalleur O, Spinewine A, Maanen CD et al.. Predictors of 1-year drug-related admissions in older multimorbid hospitalized adults. Journal of the American Geriatrics Society 2022. link 84 González-Bueno J, Sevilla-Sánchez D, Puigoriol-Juvanteny E, Molist-Brunet N, Codina-Jané C, Espaulella-Panicot J. Improving medication adherence and effective prescribing through a patient-centered prescription model in patients with multimorbidity. European journal of clinical pharmacology 2022. link 85 McCarthy C, Clyne B, Boland F, Moriarty F, Flood M, Wallace E et al.. GP-delivered medication review of polypharmacy, deprescribing, and patient priorities in older people with multimorbidity in Irish primary care (SPPiRE Study): A cluster randomised controlled trial. PLoS medicine 2022. link 86 Onder G, Vetrano DL, Palmer K, Trevisan C, Amato L, Berti F et al.. Italian guidelines on management of persons with multimorbidity and polypharmacy. Aging clinical and experimental research 2022. link 87 Carrier H, Zaytseva A, Bocquier A, Villani P, Fortin M, Verger P. General practitioners' attitude towards cooperation with other health professionals in managing patients with multimorbidity and polypharmacy: A cross-sectional study. The European journal of general practice 2022. link 88 Sallevelt BTGM, Huibers CJA, Heij JMJO, Egberts TCG, van Puijenbroek EP, Shen Z et al.. Frequency and Acceptance of Clinical Decision Support System-Generated STOPP/START Signals for Hospitalised Older Patients with Polypharmacy and Multimorbidity. Drugs & aging 2022. link 89 McCarthy C, Pericin I, Smith SM, Kiely B, Moriarty F, Wallace E et al.. Patient and general practitioner experiences of implementing a medication review intervention in older people with multimorbidity: Process evaluation of the SPPiRE trial. Health expectations : an international journal of public participation in health care and health policy 2022. link 90 Zerah L, Henrard S, Thevelin S, Feller M, Meyer-Massetti C, Knol W et al.. Performance of a trigger tool for detecting drug-related hospital admissions in older people: analysis from the OPERAM trial. Age and ageing 2022. link 91 Molist-Brunet N, Sevilla-Sánchez D, Puigoriol-Juvanteny E, Barneto-Soto M, González-Bueno J, Espaulella-Panicot J. Improving individualized prescription in patients with multimorbidity through medication review. BMC geriatrics 2022. link 92 O'Mahony D, Rochon PA. Prescribing cascades: we see only what we look for, we look for only what we know. Age and ageing 2022. link 93 Ioakeim-Skoufa I, Clerencia-Sierra M, Moreno-Juste A, Elías de Molins Peña C, Poblador-Plou B, Aza-Pascual-Salcedo M et al.. Multimorbidity Clusters in the Oldest Old: Results from the EpiChron Cohort. International journal of environmental research and public health 2022. link 94 Aubert CE, Rodondi N, Terman SW, Feller M, Schneider C, Oberle J et al.. HOSPITAL Score and LACE Index to Predict Mortality in Multimorbid Older Patients. Drugs & aging 2022. link 95 Molist-Brunet N, Sevilla-Sánchez D, Puigoriol-Juvanteny E, Bajo-Peñas L, Cantizano-Baldo I, Cabanas-Collell L et al.. Individualized Medication Review in Older People with Multimorbidity: A Comparative Analysis between Patients Living at Home and in a Nursing Home. International journal of environmental research and public health 2022. link 96 Reeve J, Maden M, Hill R, Turk A, Mahtani K, Wong G et al.. Deprescribing medicines in older people living with multimorbidity and polypharmacy: the TAILOR evidence synthesis. Health technology assessment (Winchester, England) 2022. link 97 Del Cura-González I, López-Rodríguez JA, Leiva-Fernández F, Gimeno-Feliu LA, Pico-Soler V, Bujalance-Zafra MJ et al.. Effectiveness of the MULTIPAP Plus intervention in youngest-old patients with multimorbidity and polypharmacy aimed at improving prescribing practices in primary care: study protocol of a cluster randomized trial. Trials 2022. link 98 Robertson L, Vieira R, Butler J, Johnston M, Sawhney S, Black C. Identifying multimorbidity clusters in an unselected population of hospitalised patients. Scientific reports 2022. link 99 Stokes J, Guthrie B, Mercer SW, Rice N, Sutton M. Multimorbidity combinations, costs of hospital care and potentially preventable emergency admissions in England: A cohort study. PLoS medicine 2021. link 100 Ganguli I, McGlave C, Rosenthal MB. National Trends and Outcomes Associated With Presence and Type of Usual Clinician Among Older Adults With Multimorbidity. JAMA network open 2021. link

Original source

[1]
Influence of personal beliefs on adherence to medicines in older people with multimorbidity. — Akinwale OT, Powell J Nursing older people (2026)
[2]
The gut microbiota dysbiosis in geriatric multimorbidity: Pharmacotherapeutic implications, pathophysiological mechanisms, and precision modulation strategies. — Yang D, Ren D, Zhang Y, Hao Y, Yue Y, Li Q et al. Ageing research reviews (2026)
[3]
Evaluating the impact of integrated ambulatory care on medication burden and patient-centred outcomes in older adults with multimorbidity. — Lo YT, Chen MH, Li CY, Yang YC International journal for quality in health care : journal of the International Society for Quality in Health Care (2026)
[4]
Developing an AI-Assisted Tool That Identifies Patients With Multimorbidity and Complex Polypharmacy to Improve the Process of Medication Reviews: Qualitative Interview and Focus Group Study. — Abuzour AS, Wilson SA, Woodall AA, Mair FS, Aslam A, Clegg A et al. Journal of medical Internet research (2026)
[5]
Trends over time and risk factors in inappropriate prescribing in older adults with multimorbidity and polypharmacy: a longitudinal secondary analysis of the OPERAM trial. — Huschka J, Jungo KT, Aponte Ribero V, Brockhus L, O'Mahony D, Randles M et al. Swiss medical weekly (2026)
[6]
Cross-Sectional Study on Factors Associated with Hyperpolypharmacy and Medication Adherence in Older Adults with Multimorbidity and Polypharmacy. — Beglinger S, Bretagne L, Volery F, Del Giovane C, Jungo KT, O'Mahony D et al. Drugs & aging (2026)
[7]
Hyperpolypharmacy and readmission risk among Medicare beneficiaries: the role of postdischarge care. — Ukhanova M, Highfield LD, Krause TM, Ferguson GM, Morgan RO The American journal of managed care (2026)
[8]
Quality and recommendations of guidelines for multimorbidity and polypharmacy in older adults: A systematic review. — Yang J, Li H, Chen Y, Chen T, Xiao Q, Zhao H et al. Ageing research reviews (2026)
[9]
Longitudinal pattern of multimorbidity in older adult population: latent transition analysis in 34 countries. — Al Izzati R, Pakpahan E American journal of epidemiology (2026)
[10]
Impact of an integrated transitional care programme for older patients with multimorbidity and repeated emergency department visits. — San-José A, Abadías MJ, Giménez E, Losada M, Pérez-Bocanegra C, Carrizo MG et al. Medicina clinica (2026)
[11]
Integrating exercise and medication management in geriatric care: a holistic strategy to enhance health outcomes and reduce polypharmacy. — Izquierdo M, Ramírez-Vélez R, Fiatarone Singh MA The lancet. Healthy longevity (2025)
[12]
Characterizing Aging-Related Health in Older Women with a History of Incarceration: Multimorbidity, Polypharmacy, Mortality, Frailty, and Depression. — Emerson A, Li X, Zaller N, Ramaswamy M Journal of aging and health (2025)
[13]
Multimorbidity, medications, and their association with falls, physical activity, and cognitive functions in older adults: multicenter study in Sri Lanka. — De Zoysa W, Mendis SA, Rathnayake N, Liyanage A, Palangasinghe D, Silva S et al. Scientific reports (2025)
[14]
Polypharmacy Intervention Studies in Older Adults: Challenges in Proving Benefits in Hard Clinical Outcomes. — Isop LM, Neculau AE, Kramers CK, Dima L American journal of therapeutics (2025)
[15]
Fostering collaboration: a controlled pilot study of interprofessional education for medical and pharmacy students. — Petersen M, Gehrke-Beck S, Zimmermann N, Konrad AP, Behrend R, Peters H et al. BMC medical education (2025)
[16]
Solanidine-derived CYP2D6 phenotyping elucidates phenoconversion in multimedicated geriatric patients. — Sarömba JA, Müller JP, Tupiec J, Roeth A, Kurt B, Kahles F et al. British journal of clinical pharmacology (2025)
[17]
Interventions to enhance in-home taking medication among older adults with multimorbidity/polypharmacy: a systematic review and meta-analysis. — Durán-Luque M, Robles-Muñoz MR, Velasco-García ME, Gómez-Peña C, Cobos-Vargas Á, Núñez-Núñez M et al. Frontiers in public health (2025)
[18]
Health information management of older, multimorbid patients in German primary care: feasibility and first results of the outcome measures of a cluster-randomised controlled pilot trial - HYPERION-TransCare. — Klein AA, Hanf M, Dinh TS, Brosse F, Petermann J, Piller S et al. BMC primary care (2025)
[19]
Challenges and barriers to physician decision-making for prescribing and deprescribing among patients with multimorbidity in eastern China's primary care settings: a qualitative study. — Zhou X, Han L, Farmer A, Yao M, Xia Y, Yan M et al. BMJ open (2025)
[20]
Cost effectiveness of a GP delivered medication review to reduce polypharmacy and potentially inappropriate prescribing in older patients with multimorbidity in Irish primary care: the SPPiRE cluster randomised controlled trial. — Gillespie P, Moriarty F, Smith SM, Hobbins A, Walsh S, Clyne B et al. The European journal of health economics : HEPAC : health economics in prevention and care (2025)
[21]
Solanidine-derived CYP2D6 phenotyping elucidates phenoconversion in multimedicated geriatric patients. — Sarömba JA, Müller JP, Tupiec J, Roeth A, Kurt B, Kahles F et al. British journal of clinical pharmacology (2025)
[22]
The co-occurrence of multimorbidity and polypharmacy among middle-aged and older adults in Canada: A cross-sectional study using the Canadian Longitudinal Study on Aging (CLSA) and the Canadian Primary Care Sentinel Surveillance Network (CPCSSN). — Nicholson K, Salerno J, Borhan S, Cossette B, Guenter D, Vanstone M et al. PloS one (2025)
[23]
Prevalence and Duration of Potential Drug-Drug Interactions Among US Nursing Home Residents, 2018-2020. — Reich LA, Daiello LA, Berry SD, D'Amico AM, Kiel DP, Harris DA et al. Journal of the American Geriatrics Society (2025)
[24]
Development of a virtual cross-sectional polypharmacy outpatient clinic. — Overgaard LK, Henriksen DP Danish medical journal (2025)
[25]
Primary care physicians' preferences for implementation strategies of deprescribing among patients with multimorbidity and polypharmacy in China: a qualitative study. — Xia Y, Jiang L, Yan M, Chen L, Zhou X, Wu L et al. BMC primary care (2025)
[26]
Medicines support and social prescribing to address patient priorities in multimorbidity (MIDAS): protocol for a definitive, multi-arm, cluster randomised, controlled trial in Irish general practice. — Tahsin F, Doody P, Clyne B, Kiely B, Moriarty F, Gillespie P et al. BMJ open (2025)
[27]
Inappropriate vitamin D supplementation among multimorbid older patients: a multicountry analysis. — Moutzouri E, Beglinger S, Feller M, Eichenberger A, Dalleur O, Knol W et al. BMC geriatrics (2025)
[28]
Enhancing clinical service design for multimorbidity management: A comprehensive approach to joined-up care for diabetes, chronic kidney disease, and heart failure. — Al-Chalabi S, Sinha S, Kalra PA Diabetic medicine : a journal of the British Diabetic Association (2025)
[29]
The feasibility of sharing digital audio-recordings of clinic visits online with older adults in primary care settings: A multisite trial. — Barr PJ, Masel M, Bratches RW, Carpenter-Song E, O'Malley AJ, Bruce ML et al. Patient education and counseling (2025)
[30]
A systematic review and meta-analysis of disease clusters in multimorbidity. — Ferris JK, Fiedeldey LK, Kim B, Clemens F, Irvine MA, Hosseini SH et al. Nature communications (2025)
[31]
E-Health-based, trans-sectoral, geriatric health service - Geriatric Network (GerNe). — Mohr M, Büttner M, Deuster O, Heckmann J, Huwer F, Krämer I et al. Scientific reports (2024)
[32]
Relationship between the characteristics of Japanese physicians involved in medical care for older adults and their approaches to treating older patients with multimorbidity. — Kimura T, Nomura K, Hashimoto M, Shinmura K PloS one (2024)
[33]
Inappropriate polypharmacy management versus deprescribing: A review on their relationship. — Zidan A, Awaisu A Basic & clinical pharmacology & toxicology (2024)
[34]
Multimorbidity as chronic crisis: 'Living on' with multiple long-term health conditions in a socially disadvantaged London borough. — van Blarikom E, Fudge N, Swinglehurst D Sociology of health & illness (2024)
[35]
Prevalence of multimorbidity and polypharmacy among adults and older adults: a systematic review. — Nicholson K, Liu W, Fitzpatrick D, Hardacre KA, Roberts S, Salerno J et al. The lancet. Healthy longevity (2024)
[36]
Older adults' adherence to medications and willingness to deprescribe: A substudy of a randomized clinical trial. — Weir KR, Jungo KT, Streit S British journal of clinical pharmacology (2024)
[37]
Polypharmacy in Older Patients with Multimorbidity: The Agreement Between Patient and General Practitioner-Reported Drugs Observed in a Pilot cRCT. — Schäfer L, Paulitsch M, Hanf M, Dinh TS, Klein AA, Klasing S et al. International journal of environmental research and public health (2024)
[38]
Potentially Inappropriate Medication Use in Older Adults With Multimorbidity in Taiwan. — Chang BC, Lai IH, Ng YY, Wu SC Pharmacoepidemiology and drug safety (2024)
[39]
Influence of social determinants of health on quality of life in patients with multimorbidity and polypharmacy. — Ruiz-Baena JM, Moreno-Juste A, Poblador-Plou B, Castillo-Jimena M, Calderón-Larrañaga A, Lozano-Hernández C et al. PloS one (2024)
[40]
Multidose Drug Dispensing in Community Healthcare Settings for Patients With Multimorbidity and Polypharmacy. — Martín-Oliveros A, Plaza Zamora J, Monaco A, Anitua Iriarte J, Schlageter J, Ducinskiene D et al. Inquiry : a journal of medical care organization, provision and financing (2024)
[41]
The association between medication use and health-related quality of life in multimorbid older patients with polypharmacy. — Falke C, Karapinar F, Bouvy M, Emmelot M, Belitser S, Boland B et al. European geriatric medicine (2024)
[42]
Effectiveness of an Integrated Ambulatory Care Program in Health Care and Medication Use in Patients With Multimorbidity and Polypharmacy. — Lo YT, Chen MH, Chen PH, Lu FH, Chang CM, Yang YC Quality management in health care (2024)
[43]
Multidisciplinary medication review during older patient hospitalization according to STOPP/START criteria reduces potentially inappropriate prescriptions: MoPIM cohort study. — Ortonobes S, Herranz S, Lleal M, Sevilla-Sánchez D, Jordana R, Mascaró O et al. BMC geriatrics (2024)
[44]
Structured medication reviews for adults with multimorbidity and polypharmacy in primary care: a systematic review protocol. — Lammila-Escalera E, Greenfield G, Aldakhil R, Zaman H, Neves AL, Majeed A et al. BMJ open (2024)
[45]
A mixed methods analysis of the medication review intervention centered around the use of the 'Systematic Tool to Reduce Inappropriate Prescribing' Assistant (STRIPA) in Swiss primary care practices. — Jungo KT, Deml MJ, Schalbetter F, Moor J, Feller M, Lüthold RV et al. BMC health services research (2024)
[46]
Unlocking Deprescribing Potential in Nursing Homes: Insights from a Focus Group Study with Healthcare Professionals. — Visser AGR, de-Bruijn JBGP, Spaetgens B, Winkens B, Janknegt R, Schols JMGA Drugs & aging (2024)
[47]
Recommendations and quality of multimorbidity guidelines: A systematic review. — Wang Z, Zhu D, Zhang H, Wang L, He H, Li Z et al. Ageing research reviews (2024)
[48]
Defining, identifying and addressing problematic polypharmacy within multimorbidity in primary care: a scoping review. — Tsang JY, Sperrin M, Blakeman T, Payne RA, Ashcroft D BMJ open (2024)
[49]
A qualitative exploration of barriers to efficient and effective structured medication reviews in primary care: Findings from the DynAIRx study. — Abuzour AS, Wilson SA, Woodall AA, Mair FS, Clegg A, Shantsila E et al. PloS one (2024)
[50]
A descriptive analysis of drug-drug interactions and corresponding adverse drug reactions in multimorbid older inpatients: findings from the SENATOR trial. — Simal I, Somers A, Amrouch C, Capiau A, Cherubini A, Cruz-Jentoft AJ et al. European geriatric medicine (2024)
[51]
Prevalence and patterns of multimorbidity in China during 2002-2022: A systematic review and meta-analysis. — Hu Y, Wang Z, He H, Pan L, Tu J, Shan G Ageing research reviews (2024)
[52]
Clusters of medical specialties around patients with multimorbidity - employing fuzzy c-means clustering to explore multidisciplinary collaboration. — Verhoeff M, Weil LI, Chu H, Vermeeren Y, de Groot J, Burgers JS et al. BMC health services research (2023)
[53]
Optimizing pharmacotherapy and deprescribing strategies in older adults living with multimorbidity and polypharmacy: EuGMS SIG on pharmacology position paper. — van Poelgeest E, Seppala L, Bahat G, Ilhan B, Mair A, van Marum R et al. European geriatric medicine (2023)
[54]
Increasing trend in hospitalisation due to adverse drug reactions: can we stem the tide? — Walker LE, Pirmohamed M Drug and therapeutics bulletin (2023)
[55]
Using multiple approaches to develop a physician-pharmacist collaborative care intervention to facilitate appropriate prescribing for older adults with multimorbidity. — Teng PHJ, Lun P, Tang JY, Tan KT, Ang W, Ding YY Archives of gerontology and geriatrics (2023)
[56]
Prevalence and factors predisposing to potential drug-drug interactions in a Polish community-dwelling geriatric population: An observational, cross-sectional study. — Błeszyńska-Marunowska E, Wierucki Ł, Jagiełło K, Rewiuk K, Mitręga K, Kalarus Z Advances in clinical and experimental medicine : official organ Wroclaw Medical University (2023)
[57]
Risk factors for self-reported medication adherence in community-dwelling older patients with multimorbidity and polypharmacy: a multicenter cross-sectional study. — Liu J, Yu Y, Yan S, Zeng Y, Su S, He T et al. BMC geriatrics (2023)
[58]
The EURO-FORTA (Fit fOR The Aged) List Version 2: Consensus Validation of a Clinical Tool for Improved Pharmacotherapy in Older Adults. — Pazan F, Weiss C, Wehling M Drugs & aging (2023)
[59]
Combinations of medicines in patients with polypharmacy aged 65-100 in primary care: Large variability in risks of adverse drug related and emergency hospital admissions. — Fahmi A, Wong D, Walker L, Buchan I, Pirmohamed M, Sharma A et al. PloS one (2023)
[60]
The association of parity number with multimorbidity and polypharmacy among Iranian women in the Azarcohort: a cross-sectional study. — Faramarzi E, Somi MH, Tutunchi H, Almaspour H, Sanaie S, Asemani S BMC women's health (2023)
[61]
Competences of internal medicine specialists for the management of patients with multimorbidity. EFIM multimorbidity working group position paper. — Bernabeu-Wittel M, Para O, Voicehovska J, Gómez-Huelgas R, Václavík J, Battegay E et al. European journal of internal medicine (2023)
[62]
Optimising prescribing in older adults with multimorbidity and polypharmacy in primary care (OPTICA): cluster randomised clinical trial. — Jungo KT, Ansorg AK, Floriani C, Rozsnyai Z, Schwab N, Meier R et al. BMJ (Clinical research ed.) (2023)
[63]
Psychosocial factors associated with medication burden among community-dwelling older people with multimorbidity. — Yang C, Zhu S, Hui Z, Mo Y BMC geriatrics (2023)
[64]
Medication changes and potentially inappropriate prescribing in older patients with significant polypharmacy. — McCarthy C, Flood M, Clyne B, Smith SM, Wallace E, Boland F et al. International journal of clinical pharmacy (2023)
[65]
Benzodiazepine Receptor Agonists Use and Cessation Among Multimorbid Older Adults with Polypharmacy: Secondary Analysis from the OPERAM Trial. — Sibille FX, de Saint-Hubert M, Henrard S, Aubert CE, Goto NA, Jennings E et al. Drugs & aging (2023)
[66]
Current definitions of advanced multimorbidity: a protocol for a scoping review. — Bowers SP, Black P, McCheyne L, Wilson D, Mills SEE, Agrawal U et al. BMJ open (2023)
[67]
Addressing inequity in palliative care provision for older people living with multimorbidity. Perspectives of community-dwelling older people on their palliative care needs: A scoping review. — Nicholson CJ, Combes S, Mold F, King H, Green R Palliative medicine (2023)
[68]
Effect on life expectancy of temporal sequence in a multimorbidity cluster of psychosis, diabetes, and congestive heart failure among 1·7 million individuals in Wales with 20-year follow-up: a retrospective cohort study using linked data. — Owen RK, Lyons J, Akbari A, Guthrie B, Agrawal U, Alexander DC et al. The Lancet. Public health (2023)
[69]
Sociodemographic characteristics and longitudinal progression of multimorbidity: A multistate modelling analysis of a large primary care records dataset in England. — Chen S, Marshall T, Jackson C, Cooper J, Crowe F, Nirantharakumar K et al. PLoS medicine (2023)
[70]
Multimorbidity and polypharmacy: a risk factor for older patients. — Cucinotta D Acta bio-medica : Atenei Parmensis (2022)
[71]
Pharmacogenetic interventions to improve outcomes in patients with multimorbidity or prescribed polypharmacy: a systematic review. — O'Shea J, Ledwidge M, Gallagher J, Keenan C, Ryan C The pharmacogenomics journal (2022)
[72]
Validation protocol of the LESS-CHRON deprescription tool in multimorbidity patients. LESS-CHRON-VALIDATION Project. — Rodríguez-de Francisco L, Rodríguez-Pérez A, Mejías-Trueba M, Beobide-Tellería I, Juanes-Borrego AM, Saavedra-Quirós V et al. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria (2022)
[73]
Keeping in balance on the multimorbidity tightrope: A narrative analysis of older patients' experiences of living with and managing multimorbidity. — Fudge N, Swinglehurst D Social science & medicine (1982) (2022)
[74]
Intervention elements and behavior change techniques to improve prescribing for older adults with multimorbidity in Singapore: a modified Delphi study. — Tang JY, Lun P, Teng PHJ, Ang W, Tan KT, Ding YY European geriatric medicine (2022)
[75]
Fifteen-year trajectories of multimorbidity and polypharmacy in Dutch primary care-A longitudinal analysis of age and sex patterns. — Vos R, Boesten J, van den Akker M PloS one (2022)
[76]
Interventions to address polypharmacy in older adults living with multimorbidity: Review of reviews. — Ali MU, Sherifali D, Fitzpatrick-Lewis D, Kenny M, Lamarche L, Raina P et al. Canadian family physician Medecin de famille canadien (2022)
[77]
Cost-effectiveness of a structured medication review approach for multimorbid older adults: Within-trial analysis of the OPERAM study. — Salari P, O'Mahony C, Henrard S, Welsing P, Bhadhuri A, Schur N et al. PloS one (2022)
[78]
Identifying multimorbidity clusters with the highest primary care use: 15 years of evidence from a multi-ethnic metropolitan population. — Soley-Bori M, Bisquera A, Ashworth M, Wang Y, Durbaba S, Dodhia H et al. The British journal of general practice : the journal of the Royal College of General Practitioners (2022)
[79]
Rational medication management mode and its implementation effect for the elderly with multimorbidity: A prospective cohort study in China. — Tang Q, Wan L, Lu J, Wu W, Wu H, Liu Z et al. Frontiers in public health (2022)
[80]
Risk factors for potentially inappropriate medication use in older adults: a cohort study. — de Araújo NC, Silveira EA, Mota BG, Guimarães RA, Modesto ACF, Pagotto V International journal of clinical pharmacy (2022)
[81]
Hospital physicians' and older patients' agreement with individualised STOPP/START-based medication optimisation recommendations in a clinical trial setting. — Huibers CJA, Sallevelt BTGM, Heij JMJO, O'Mahony D, Rodondi N, Dalleur O et al. European geriatric medicine (2022)
[82]
Optimising a person-centred approach to stopping medicines in older people with multimorbidity and polypharmacy using the DExTruS framework: a realist review. — Turk A, Wong G, Mahtani KR, Maden M, Hill R, Ranson E et al. BMC medicine (2022)
[83]
Predictors of 1-year drug-related admissions in older multimorbid hospitalized adults. — Aubert CE, Rodondi N, Netzer S, Dalleur O, Spinewine A, Maanen CD et al. Journal of the American Geriatrics Society (2022)
[84]
Improving medication adherence and effective prescribing through a patient-centered prescription model in patients with multimorbidity. — González-Bueno J, Sevilla-Sánchez D, Puigoriol-Juvanteny E, Molist-Brunet N, Codina-Jané C, Espaulella-Panicot J European journal of clinical pharmacology (2022)
[85]
GP-delivered medication review of polypharmacy, deprescribing, and patient priorities in older people with multimorbidity in Irish primary care (SPPiRE Study): A cluster randomised controlled trial. — McCarthy C, Clyne B, Boland F, Moriarty F, Flood M, Wallace E et al. PLoS medicine (2022)
[86]
Italian guidelines on management of persons with multimorbidity and polypharmacy. — Onder G, Vetrano DL, Palmer K, Trevisan C, Amato L, Berti F et al. Aging clinical and experimental research (2022)
[87]
General practitioners' attitude towards cooperation with other health professionals in managing patients with multimorbidity and polypharmacy: A cross-sectional study. — Carrier H, Zaytseva A, Bocquier A, Villani P, Fortin M, Verger P The European journal of general practice (2022)
[88]
Frequency and Acceptance of Clinical Decision Support System-Generated STOPP/START Signals for Hospitalised Older Patients with Polypharmacy and Multimorbidity. — Sallevelt BTGM, Huibers CJA, Heij JMJO, Egberts TCG, van Puijenbroek EP, Shen Z et al. Drugs & aging (2022)
[89]
Patient and general practitioner experiences of implementing a medication review intervention in older people with multimorbidity: Process evaluation of the SPPiRE trial. — McCarthy C, Pericin I, Smith SM, Kiely B, Moriarty F, Wallace E et al. Health expectations : an international journal of public participation in health care and health policy (2022)
[90]
Performance of a trigger tool for detecting drug-related hospital admissions in older people: analysis from the OPERAM trial. — Zerah L, Henrard S, Thevelin S, Feller M, Meyer-Massetti C, Knol W et al. Age and ageing (2022)
[91]
Improving individualized prescription in patients with multimorbidity through medication review. — Molist-Brunet N, Sevilla-Sánchez D, Puigoriol-Juvanteny E, Barneto-Soto M, González-Bueno J, Espaulella-Panicot J BMC geriatrics (2022)
[92]
Prescribing cascades: we see only what we look for, we look for only what we know. — O'Mahony D, Rochon PA Age and ageing (2022)
[93]
Multimorbidity Clusters in the Oldest Old: Results from the EpiChron Cohort. — Ioakeim-Skoufa I, Clerencia-Sierra M, Moreno-Juste A, Elías de Molins Peña C, Poblador-Plou B, Aza-Pascual-Salcedo M et al. International journal of environmental research and public health (2022)
[94]
HOSPITAL Score and LACE Index to Predict Mortality in Multimorbid Older Patients. — Aubert CE, Rodondi N, Terman SW, Feller M, Schneider C, Oberle J et al. Drugs & aging (2022)
[95]
Individualized Medication Review in Older People with Multimorbidity: A Comparative Analysis between Patients Living at Home and in a Nursing Home. — Molist-Brunet N, Sevilla-Sánchez D, Puigoriol-Juvanteny E, Bajo-Peñas L, Cantizano-Baldo I, Cabanas-Collell L et al. International journal of environmental research and public health (2022)
[96]
Deprescribing medicines in older people living with multimorbidity and polypharmacy: the TAILOR evidence synthesis. — Reeve J, Maden M, Hill R, Turk A, Mahtani K, Wong G et al. Health technology assessment (Winchester, England) (2022)
[97]
Effectiveness of the MULTIPAP Plus intervention in youngest-old patients with multimorbidity and polypharmacy aimed at improving prescribing practices in primary care: study protocol of a cluster randomized trial. — Del Cura-González I, López-Rodríguez JA, Leiva-Fernández F, Gimeno-Feliu LA, Pico-Soler V, Bujalance-Zafra MJ et al. Trials (2022)
[98]
Identifying multimorbidity clusters in an unselected population of hospitalised patients. — Robertson L, Vieira R, Butler J, Johnston M, Sawhney S, Black C Scientific reports (2022)
[99]
Multimorbidity combinations, costs of hospital care and potentially preventable emergency admissions in England: A cohort study. — Stokes J, Guthrie B, Mercer SW, Rice N, Sutton M PLoS medicine (2021)
[100]
National Trends and Outcomes Associated With Presence and Type of Usual Clinician Among Older Adults With Multimorbidity. — Ganguli I, McGlave C, Rosenthal MB JAMA network open (2021)

Share:Twitter Reddit LinkedIn